Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages 113-119

  Papa, Alfredo ^a   Felice, Carla ^a   Marzo, Manuela ^a   Andrisani, Gianluca ^a   Armuzzi, Alessandro ^a   Covino, Marcello ^a   Mocci, Giammarco ^a   Pugliese, Daniela ^a   De Vitis, Italo ^a   Gasbarrini, Antonio ^a   Rapaccini, Gian Lodovico ^a   Guidi, Luisa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adalimumab; Anti TNF ; Hepatitis B virus; Hepatitis C virus; Infliximab

Indexed keywords

AZATHIOPRINE; CERTOLIZUMAB PEGOL; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; ENTERITIS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RNA, VIRAL; ROC CURVE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84872495292     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.03.001     Document Type: Article

References (25)

1. Longo F., Hebuterne X., Tran A., et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol 2000, 24:77-81.
2. Biancone L., Pavia M., Del Vecchio Blanco G., et al. Hepatitis B and C infection in Crohn's disease. Inflamm Bowel Dis 2001, 7:287-294.
3. Cheavaux J.B., Nani A., Oussalah A., et al. Prevalence of Hepatitis B and C and risk factor for nonvaccination in inflammatory bowel disease patients in northeast France. Inflamm Bowel Dis 2010, 16:916-924.
4. Loras C., Saro C., Gonzales-Huix F., et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009, 104:57-63.
5. Katsanos K.H., Tsianos V.E., Zois C.D., et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohn's Colitis 2010, 4:450-465.
6. Rutgeerts P., Vermeire S., Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009, 136:1182-1197.
7. Esteve M., Saro C., Gonzales-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
8. Millonig G., Kern M., Ludwiczek O., et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 2006, 12:974-976.
9. Esteve M., Loras C., Gonzales-Huix F., et al. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007, 13:1450-1451.
10. Colbert C., Chavarria A., Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007, 13:1453-1454.
11. Madonia S., Orlando A., Scimeca D., et al. Occult hepatitis B and infliximab-induced reactivation. Inflamm Bowel Dis 2007, 13:508-509.
12. Shale M.J., Seow C.H., Coffin C.S., et al. S. Review article: chronic viral infection in the anti-tumor necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:20-34.
13. Loras C., Gisbert J.P., Minguez M., et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-1346.
14. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel 0disease. J Crohns Colitis 2009, 3:47-91.
15. Hou J.K., Velayos F., Terrault N., et al. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:925-932.
16. Papa A., Mocci G., Bonizzi M., et al. Use of infliximab in particular clinical settings: management based on current evidences. Am J Gastroenterol 2009, 104:1575-1586.
17. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:619-633.
18. Morisco F., Castiglione F., Rispo A., et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011, 43(Suppl. 1):S40-S48.
19. Horn T.L., Reynolds J., de Villiers W., Penã L.R. Hepatitis C virus and inflammatory bowel disease. Dig Dis Sci 2009, 54:1171-1177.
20. Fabris P., Baldo V., Baldovin T., et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008, 42:527-532.
21. Cozzolongo R., Osella A.R., Elba S., et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol 2009, 104:2740-2746.
22. Van Damme P., Hepatitis B. vaccination programmes in Europe - an update. Vaccine 2001, 19:2375-2379.
23. Romanò L., Paladini S., Tagliacarne C., et al. The changing face of the epidemiology of type A, B, and D viral hepatitis in Italy, following the implementation of vaccination. Vaccine 2009, 27:3439-3442.
24. Tolentino Y.F., Fogaca H.S., Zaltman C., et al. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. World J Gastroenterol 2008, 14:3201-3206.
25. Katz L.H., Fraser A., Gafter-Gvilli A., et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008, 15:89-102.